• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Mytrus launches innovation advisory board

Mytrus launches innovation advisory board

March 19, 2014
CenterWatch Staff

Mytrus, a provider of electronic informed consent and e-clinical technologies, has created a new Innovation Advisory Board comprised of industry experts to help shape the future of its clinical products and services.

"The members of our new innovation board have held key positions in the pharmaceutical industry throughout their careers and have a long tradition of innovating improvements in clinical research," said Anthony Costello, Mytrus CEO, who also will serve on the innovation board.

Costello noted research shows how better informed and more engaged patients lead to better research data and faster drug development timelines. "This group of experts has long recognized the importance of patient centricity in research and their input into our line of clinical trials technologies will be invaluable in helping us break new ground in trial improvement," he said.

The six board members are:

  • Steven Cummings, co-founder and chief scientific officer of Mytrus, and Innovator-in-Residence at Roche-Genentech
  • David G. Forster, JD, MA, CIP, chief compliance officer at WIRB-Copernicus Group
  • Clay Johnston, M.D., Ph.D., dean of medicine at the new University of Texas Dell Medical School
  • Garry Neil, global head of R&D at Medgenics and a founder/director and former CEO of TransCelerate Biopharma
  • John Orloff, M.D., global head of clinical development at Merck Serono
  • Jane Perlmutter, M.D., Ph.D., MBA, a psychologist and patient advocate on the CTTI on informed consent.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing